Serum Institute of India

50954044072_6ca3cbf214_4k

Could the New BA.2.75 Sub-Variant Lead to Another COVID-19 Wave in India?

Dr Vipin Vashishtha 05/07/2022

Just as the BA.5 sub-variant was poised to take...

NTAGI Panel Recommends Covovax for 12-17 Age Group in Vaccination Drive

India's drug regulator had approved Covovax for restricted use...

COVID-19 booster dose

Interview | ‘Fears of Fourth COVID Wave in India Currently Misplaced’

Banjot Kaur 15/04/2022

'With almost everybody having been infected once and a...

People receive a dose of COVISHIELD vaccine

India Announces Boosters for All Adults. But Whom Will They Really Benefit?

Vasudevan Mukunth and Banjot Kaur 09/04/2022

In the absence of scientific evidence in favour of...

NTAGI To Review Covovax Data This Week

India's drug regulator had approved Covovax for restricted use...

A health worker holds a vial with doses of the Oxford-AstraZeneca vaccine, marketed by the Serum Institute of India (SII) as COVISHIELD, against the coronavirus disease (COVID-19), in Paramaribo

Second Covishield Dose Can Be Given Between 8-16 Weeks After First: NTAGI

The National Technical Advisory Group on Immunisation (NTAGI) has...

mat-napo-sOTG_4n82Hk-unsplash(1)

‘Insult To Poorest Countries’: UK Could Offset Foreign Aid With Vaccine Donations

Samuel Horti, Rosa Furneaux and Samuel Lovett 16/03/2022

Because of the structure of the UK’s budget, any...